Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

224
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
224
Cofactors and Coenzymes01:27

Cofactors and Coenzymes

83.1K
Enzymes require additional components for proper function. There are two such classes of molecules: cofactors and coenzymes. Cofactors are metallic ions and coenzymes are non-protein organic molecules. Both of these types of helper molecule can be tightly bound to the enzyme or bound only when the substrate binds.
83.1K
Mismatch Repair01:20

Mismatch Repair

5.1K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.1K
Translation01:31

Translation

15.2K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
15.2K
Role of Reduced Coenzymes NADH and FADH₂01:29

Role of Reduced Coenzymes NADH and FADH₂

12.2K
The energy released from the breakdown of the chemical bonds within nutrients can be stored either through the reduction of electron carriers or in the bonds of adenosine triphosphate (ATP). In living systems, a small class of compounds functions as mobile electron carriers, molecules that bind to and shuttle high-energy electrons between compounds in pathways. The principal electron carriers that will be considered originate from the B vitamin group and are derivatives of nucleotides; they are...
12.2K
Vitamins01:30

Vitamins

908
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
908

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired gephyrin G-domain trimerization and phase separation in a patient with developmental epileptic encephalopathy.

EMBO molecular medicine·2026
Same author

The Interplay between Gut Microbiota and Diet-Induced Kidney Protection.

Kidney360·2026
Same author

Clinical and biochemical footprints of inherited cofactor disorders.

Molecular genetics and metabolism·2026
Same author

An electrochemical perspective on human sulfite oxidase as a potential nitrite reductase.

Journal of inorganic biochemistry·2025
Same author

Measurement of ground reaction forces in cats after total hip replacement.

Journal of feline medicine and surgery·2024
Same author

cPMP rescue of a neonate with severe molybdenum cofactor deficiency after serendipitous early diagnosis, and characterisation of a novel MOCS1 variant.

Molecular genetics and metabolism·2024

Related Experiment Video

Updated: Aug 23, 2025

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase COX/SDH Double-labeling Histochemistry
06:53

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase COX/SDH Double-labeling Histochemistry

Published on: November 23, 2011

36.9K

Molybdenum Cofactor Deficiency in Humans.

Lena Johannes1, Chun-Yu Fu1, Günter Schwarz1

  • 1Institute of Biochemistry, Department of Chemistry & Center for Molecular Medicine Cologne, University of Cologne, 50674 Cologne, Germany.

Molecules (Basel, Switzerland)
|October 27, 2022
PubMed
Summary

Molybdenum cofactor deficiency causes severe neurological issues due to toxic sulfite buildup. Treatment with cyclic pyranopterin monophosphate (cPMP) can help MoCD type A by restoring balance, but early intervention is key.

Keywords:
GPHNMOCS1MOCS2MOCS3NulibrycPMPcyclic pyranopterin monophosphatemolybdenum cofactor deficiencymolybdopterinsulfite oxidase

More Related Videos

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.3K
Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.3K

Related Experiment Videos

Last Updated: Aug 23, 2025

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase COX/SDH Double-labeling Histochemistry
06:53

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase COX/SDH Double-labeling Histochemistry

Published on: November 23, 2011

36.9K
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.3K
Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.3K

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Molybdenum cofactor (Moco) deficiency (MoCD) presents as neonatal-onset epileptic encephalopathy and dystonia.
  • It results from impaired Moco biosynthesis, leading to loss of sulfite oxidase (SOX) activity.
  • This causes toxic sulfite accumulation and altered cysteine homeostasis.

Purpose of the Study:

  • To review the metabolic alterations in MoCD, focusing on cysteine homeostasis.
  • To discuss therapeutic strategies for MoCD, particularly type A.
  • To propose novel interventions for MoCD types B/C and SOX deficiency.

Main Methods:

  • Review of existing literature on MoCD pathophysiology and treatment.
  • Analysis of metabolic pathways affected by Moco deficiency.
  • Exploration of potential therapeutic targets for cysteine homeostasis.

Main Results:

  • MoCD types A, B, and C are defined by specific blocks in Moco biosynthesis.
  • Cyclic pyranopterin monophosphate (cPMP) therapy is effective for MoCD type A, mitigating sulfite toxicity.
  • Clinical outcomes depend on pre-treatment brain injury severity.

Conclusions:

  • Understanding cysteine homeostasis is crucial for managing MoCD.
  • cPMP substitution therapy offers a viable treatment for MoCD type A.
  • Novel therapeutic approaches are needed for MoCD types B/C and SOX deficiency to address metabolic imbalances.